LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial - Dowlati, Afshin; Harvey, R. Donald; Carvajal, Richard D.; Hamid, Omid; Klempner, Samuel J.; Kauh, John Sae Wook; Peterson, Daniel A.; Yu, Danni; Chapman, Sonya C.; Szpurka, Anna M.; Carlsen, Michelle; Quinlan, Tonya; et al. (Investigational new drugs, 2021)
Keywords: Administration, Intravenous; Adolescent; Adult; Adverse events; Aged; Anemia; Anorexia; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Cohort Studies; Colonies; Colony-stimulating factor; Diarrhea; Dosage; Dose-Response Relationship, Drug; Female; Fever; Heart; Humans; Immunogenicity; Immunotherapy; Intravenous administration; L-Lactate dehydrogenase; Lactate dehydrogenase; Lactic acid; Macrophage colony-stimulating factor; Macrophages; Male; Mathematical analysis; Medicine; Medicine & Public Health; Metastases; Middle Aged; Monoclonal antibodies; Nausea; Neoplasms - drug therapy; Oncology; Pancreatitis; Patients; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Phase I Studies; Receptors; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor - antagonists & inhibitors; Resistance factors; Rhabdomyolysis; Solid tumors; Toxicity; Tumors; Ventricle; Vomiting; Weight; Young Adult; Advanced solid tumor; Immunotherapy; LY3022855; CSF-1; IL-34; Tumor -associated macrophages; CSF-1R inhibitor